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Mouse and human induced pluripotent stem cells (iPSCs) may represent a novel approach for modeling
diabetes. Taking this into consideration, the aim of this study was to generate and evaluate differentiation
potential of iPSCs from lepdb/db (db/db) mice, the model of diabetes type 2 as well as from patients with
Maturity Onset Diabetes of the Young 3 (HNF1A MODY). Murine iPSC colonies from both wild type and
db/db mice were positive for markers of pluripotency: Oct3/4A, Nanog, SSEA1, CDy1 and alkaline
phosphatase and differentiated in vitro and in vivo into cells originating from three germ layers. However,
our results suggest impaired differentiation of db/db cells into endothelial progenitor-like cells expressing
CD34 and Tie2 markers and their reduced angiogenic potential. Human control and HNF1A MODY
reprogrammed cells also expressed pluripotency markers: OCT3/4A, SSEA4, TRA-1–60, TRA-1-81, formed
embryoid bodies (EBs) and differentiated into cells of three germ layers. Additionally, insulin expressing
cells were obtained from those partially reprogrammed cells with direct as well as EB-mediated
differentiation method. Our findings indicate that disease-specific iPSCs may help to better understand the
mechanisms responsible for defective insulin production or vascular dysfunction upon differentiation
toward cell types affected by diabetes.
D
iabetes mellitus is a group of complex metabolic diseases affecting more than 300 million people world-
wide1. The most common form is type 2 diabetes (T2D) which is characterized by the lack of proper
response to insulin in the peripheral tissues, a phenomenon known as the insulin resistance2. Additionally,
T2D is accompanied by relative insulin deficiency resulting from defects in the secretion of this hormone3.
Among others, this disease is also closely associated with cardiovascular complications, with endothelial cells
being significantly affected4. Lepdb/db is a mouse strain frequently utilized as T2D model with the mutation in leptin
receptor resulting in hyperphagy, obesity, hyperinsulinemia and hyperglycemia, the latter three reflecting clinical
features of T2D patients5,6. Importantly, animal models based on disturbed leptin activity are often used to test
new therapeutic approaches against T2D7,8.
In contrast to T2D, monogenic forms of diabetes are rather rare, with the maturity onset of diabetes of the
young (MODY) being the most frequent among them, constituting 1–2% of diabetic cases9. HNF1A MODY
(MODY3) is the most common form which results from the mutations in hepatocyte nuclear factor 1 alpha
(HNF1A) gene10. This nuclear receptor is expressed in several organs, including pancreas, and controls the
production of multiple factors responsible for glucose uptake, glycolysis and mitochondrial metabolism.
Patients with MODY3 usually suffer from postprandial hyperglycemia and require pharmacological treatment
with sulphonylureas or, in later stage, with insulin11. The molecular basis of this disease, similarly to T2D, has been
characterized with the application of cell lines and animal models12, however utilization of patient-specific
biological material could significantly enlarge our knowledge on the mechanisms of defective insulin production
by the pancreatic b cells.
Induced pluripotent stem cells (iPSCs) which resemble embryonic stem cells with their infinite self-renewal
capacity as well as the ability to differentiate into all cell types constituting adult organism13,14, may provide the
new possible source of such patient-specific material. Indeed, many groups demonstrated a feasibility of gen-
erating human iPSCs from patients suffering from different illnesses including metabolic disorders like type 1 and
2 of diabetes15,16 as wells as five forms of MODYs17,18. Some of these studies described differentiation of hiPSCs
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for different types of MODYs. Additionally, iPSCs have been
obtained from murine model of type 1 diabetes19 but not the others.
Here we report successful generation of induced pluripotent stem
cells from the Lepdb/db mice as the animal model of T2D as well as
reprogrammed cells from patients diagnosed with HNF1A MODY.
Additionally, this study demonstrates the feasibility of production of
such cells to investigate the effects of diabetes on different cell types.
Generated iPSCs can be further utilized to analyze the molecular
mechanisms responsible for pathophysiology of diabetic disorders
or be used for drug screening.
Results
Generation and characterization of mouse db/db iPSCs. Trans-
duction of tail tip fibroblasts isolated from control wild type (WT)
and Lepdb/db mice with STEMCCA lentiviral vectors resulted in
generation of multiple colonies (within 2–3 weeks of reprogramming
process) resembling mouse embryonic stem cells which could be
further picked up and expanded (Figure 1A). No differences between
cells from WT and Lepdb/db mice were observed. This indicates that
leptin signaling, which is disturbed in db/db cells is not required for
proper reprogramming outcome. Additionally, no changes in
morphology of db/db iPSCs were noticed in comparison to control
counterparts as well as in the expression of pluripotency markers like
Oct3/4A, Nanog and Sox2, both at mRNA and protein levels
(Figure 1A–C). Expression of these transcription factors, which are
the crucial components of self-renewal- and pluripotency-regulating
signaling network, additionally indicated successful generation of
induced pluripotent stem cells. Both WT and db/db iPSCs presented
abundantly the SSEA1 carbohydrate epitopes, bound CDy1 dye
(Figure 1C), and expressed alkaline phosphatase (Figure 1D). On the
other hand, Hmox1 (heme oxygenase-1), Prt4 (proteoglycan-4), and
Agt (angiotensinogen) showed a tendency toward lower expressions in
db/db iPSCs than in WT cells (Figure 1E). This observation seems
interesting, as proteoglycan-4 can promote development of
hemangioblasts20 and similar role has been ascribed to the
angiotensin converting enzyme21, whereas heme oxygenase-1 is a
proangiogenic enzyme necessary for proper function of endothelial
progenitors22.
To further verify the pluripotency of iPSCs, they were subjected to
spontaneous differentiation process through the formation of
embryoid bodies (Figure 2). Indeed, after removal of feeder layer
and LIF (leukemia inhibitory factor) stimulation, control and db/
db iPSCs generated EBs which adhered to gelatin-coated wells
(Figure 2A,B). Importantly, immunofluorescence analysis confirmed
the expression of markers of different germ layers in the control and
db/db cells that further outgrew from the adhered EBs (Figure 2C,D).
Finally, subcutaneous injection of either control or db/db iPSCs into
immunocompromised mice resulted in formation of teratomas
which were composed of tissues characteristic for endoderm, meso-
derm and ectoderm (Figure 2E,F). This experiment proved that both
WT iPSCs and those generated from Lepdb/db animals were pluripo-
tent. Additionally, this demonstrated that functional leptin receptor
is not crucial for the maintenance of pluripotency in iPSCs.
Endothelial differentiation of control and db/db iPSCs. To
stimulate endothelial differentiation, control and db/db iPSCs were
seeded on collagen IV to induce differentiation into mesoderm
lineages and subsequently cultured on fibronectin in the presence
of vascular endothelial growth factor (VEGF) to direct the process
toward endothelial cells23. Of note, the fraction of CD341Tie-21
subpopulation was much lower within differentiating db/db cells
than in control counterparts (14.3% versus 88.4% at day 60 of
differentiation, Figure 3A), suggesting that functional leptin
signaling might influence this process. Nevertheless, either control
or db/db cells acquired characteristic endothelial-like cobblestone
morphology (Figure 3B), and expressed endothelial markers, such
as von Willebrand Factor (vWF), phosphorylated endothelial nitric
oxide synthase (eNOS), and vascular endothelial growth factor
receptor 1 (Flt-1) (Figure 3C). Phosphorylation of eNOS protein
indicated its enzymatic activity. Indeed, the iPSC-derived
endothelial progenitor-like cells produced nitric oxide (NO), with
the same efficacy for both genotypes (Figure 3D).
Then, we compared the angiogenic potential of the iPSC-derived
cells using a capillary sprouting assay (Figure 3E). Cells were sus-
pended in medium containing methyl cellulose and seeded in U-
shaped 96-well plate to form spheroids, which were subsequently
embedded in collagen and stimulated with VEGF to produce capil-
lary-like sprouts. The number and length of sprouts were analyzed
after 48 h, but in WT spheroids the outgrowth of sprouts was visible
already after 24 h. In contrast, db/db spheroids formed almost no
capillary-like structures (Figure 3E,F). Namely, we demonstrated a
significant impairment both in number and length of capillary like
structures (Figure 3F). This observation suggests that cells obtained
after endothelial differentiation of db/db iPSCs display impaired
angiogenic potential, the feature typical for endothelial cells isolated
from db/db mice. Indeed, we found a very similar impairment when
spheroids were formed by CD341 primary endothelial cells isolated
from the lungs of wild type or db/db mice (Figure 3G).
Generation and characterization of HNF1A MODY reprogrammed
cells. Similarly to mouse tail tip fibroblasts, human primary skin
fibroblasts isolated from non-diabetic controls and HNF1A MODY
patients were successfully reprogrammed using STEMCCA vectors.
Multiple colonies were obtained 3 to 4 weeks after lentiviral
transduction (Figure 4A). Since initially we encountered very low
efficiency of successful expansion of reprogrammed after picking up
and passaging single colonies, a different procedure was tested,
where the generated colonies were detached together with non-
reprogrammed fibroblasts and seeded onto gelatin-coated wells.
After 0.5 h most of the fibroblasts, in contrast to reprogrammed
cells, had already attached to the bottom of the well, which enabled
a significant enrichment of the floating cell population with
reprogrammed cells. Non-adhered cells were collected, seeded on
Matrigel and further cultured. This step was helpful in successful
expansion of human reprogrammed cells in our hands.
Further characterization of the obtained control and HNF1A
MODY reprogrammed cells confirmed silencing of lentiviral repro-
gramming construct in two of four lines (Ctr Repro 2 and HNF1A
MODY Repro 1, Figure 4B). Both control and HNF1A MODY cells
expressed pluripotency markers, as shown using immunofluores-
cence analysis of OCT3/4A, SSEA4, TRA-1-60, and TRA-1-81
(Figure 4C,D). Concomitantly, they formed embryoid bodies after
removal of bFGF stimulation and seeding on non-adherent dishes
(Figure 5A). When EBs were transferred to the adherent, Matrigel-
coated wells, the outgrowth of differentiating cells could be detected
in the following days (Figure 5A). These cells expressed markers
characteristic for all three germ layers, confirming the broad differ-
entiation potential of generated human reprogrammed cells
(Figure 5 A,B). Nevertheless, despite multiple cell injections into
immunocompromised mice, no teratoma generation was observed.
In case of Ctr Repro 2, one of the injections resulted in development
of malignant epithelial tumor (Figure 5 C).
Differentiation of control and HNF1A MODY reprogrammed cells
toward a pancreatic lineage. To assess the potential of HNF1A
MODY reprogrammed cells to differentiate toward insulin-
producing cells, two methods have been tested, namely direct and
embryoid bodies-mediated differentiation. The efficacies of these
approaches were evaluated by analysing the expression of specific
markers at mRNA levels. RT-PCR assay was employed to
demonstrate expression of i) SOX17 and FOXA2, markers of
definitive endoderm (DE, day 1–3), ii) HNF4a, marker of gut
endoderm (GTE, d3–9), and iii) HNF6, PDX1, HB9, NKX6.1 and
www.nature.com/scientificreports
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Figure 1 | Generation of wild type (WT) and Lepdb/db (db/db) iPS cells. (A). Morphology of WT and db/db iPS cells. Representative pictures (scale bar –
100 mm). (B). Expression of pluripotency markers: Oct3/4A, Nanog and Sox2 in control and db/db iPSCs. Quantitative RT-PCR analysis. N 5 3. (C).
Immunofluorescence staining of pluripotency markers: Oct3/4A, Nanog, SSEA1 and CDy1 in WT and db/db iPS cells (scale bar – 100 mm). (D).
Expression of alkaline phosphatase in WT and db/db iPS cells. Representative pictures (scale bar – 100 mm). (E). Expression of genes associated with
endothelial lineage development: HO-1, proteoglycan-4 and angiotensinogen. Quantitative RT-PCR analysis. N 5 2. EF2 gene was used as housekeeping
gene. Each bar represents mean 1 SEM. The numerical data presented in Fig. 1B and 1E were not statistically significant.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 5 : 8597 | DOI: 10.1038/srep08597 3
Figure 2 | Differentiation potential of wild type (WT) and Lepdb/db (db/db) iPS cells. (A). Embryoid bodies formed from iPS cells after seeding on non-
adherent dishes without LIF stimulation (scale bar – 100 mm). (B). Outgrowth of cells from embryoid bodies after adherence to gelatin-coated dishes.
Outgrowing cells were further differentiating (scale bar – 100 mm). (C,D). Immunofluorescence staining of markers characteristic for three different germ
layers after two weeks of spontaneous differentiation via embryoid bodies of WT iPS cells (C) or db/db iPS cells (D). Gata4 – marker of early and defined
endoderm as well as mesoderm; nestin – marker of ectoderm; vimentin – marker of mesoderm. Representative pictures (scale bar – 100 mm). (E,F).
Teratoma formation assay – representative pictures demonstrating tissues originating from three germ layers within a tumor developed after
subcutaneous injection of WT iPS cells (E, N 5 3) or db/db iPS cells (F, N 5 4) into immunocompromised mice. Upper – muscles (mesodrem), middle –
epidermis (ectoderm), bottom – ciliated epithelium (endoderm) (scale bar – 100 mm).
www.nature.com/scientificreports
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Figure 3 | Differentiation of wild type (WT) and Lepdb/db (db/db) iPS cells into endothelial progenitor-like cells. (A). FACS analysis of CD341Tie-21
population in WT and db/db iPSC-derived cells before differentiation (day 0) and after establishing the differentiated cell lines (day 60). Representative
dot-plots. Control – unstained cells. (B). Morphology of WT and db/db iPSC-derived endothelial progenitor-like cell lines at 130th day of culture.
Representative pictures. (C). Immunofluorescence staining of von Willebrand Factor (vWF), phosphorylated endothelial nitric oxide synthase (phosp
eNOS), and vascular endothelial growth factor receptor 1 (Flt-1) in WT and db/db iPSC-derived endothelial progenitor-like cells (scale bar – 100 mm).
(D). Nitric oxide production by WT and db/db iPSC-derived endothelial progenitor-like cells. Gas-phase chemiluminescence reaction (n 5 3). (E).
Sprouting spheres embedded in collagen, generated from WT and db/db iPSC-derived endothelial progenitor-like cells or lung primary CD341
endothelial cells isolated from WT and db/db mice. Representative pictures (scale bar – 100 mm). (F,G). Average number of sprouts and total length of
sprouts measured for sprouting spheres embedded in collagen, generated from WT (n 5 12 spheres) and Lepdb/db (n 5 10 spheres) iPSC-derived
endothelial progenitor-like cells (F) or lung primary CD341 endothelial cells isolated from WT (N 5 5) and db/db (N 5 4) mice (G). Each bar represents
mean 1 SEM. * p , 0.05, *** p , 0.001.
www.nature.com/scientificreports
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NKX2.2, markers of pancreatic progenitor cells (PP, d9–19). The five
latter mentioned markers were analyzed along with expression of
insulin (INS) in the last step of development toward b-like cells
(d19–25). A scheme describing the stages and time points of
differentiation as well as photos of differentiating cells are shown in
Figure 6 A&B. For the EB-based approach only three time points were
tested, namely day 19th, 24th and 30th (day 5th, 10th and 16th upon
seeding of cells on collagen I-coated plates (Figure 6C). To monitor
the progression, the same markers as in the direct differentiation were
analysed (SOX17, FOXA2, HNF4a at day 19th; HNF6, PDX1, HB9 and
NKX6.1 at day 24th; NKX2.2 and insulin after 30 days of
differentiation). Morphology of differentiating cells in EB-based
method is shown in Figure 6D.
In case of the direct approach, all specific markers were detectable
in differentiating cell lines either derived from control or HNF1A
MODY patients (Figure 7A). Similarly, in the method based on EB-
Figure 4 | Generation of human reprogrammed cells from fibroblasts of control healthy subjects and HNF1A MODY patients. (A). Morphology of cells
from healthy subject before (day 0) and 13 days after transduction (day 13) with hSTEMCCA lentiviral vectors. Colonies resembling human
embryonic stem cells, visible at day 13, were further expanded (expanded colony, shown at passage 2). GFP - expression of GFP in human primary fibroblast
isolated from HNF1A MODY patients, 72 after transduction with control (FUGW) lentiviral vectors. Representative pictures (scale bar – 100 mm). (B).
Analysis of hSTEMCCA construct silencing in established control (effective silencing in Ctr Repro 2 cell line) and HNF1A MODY reprogrammed cells
(effective silencing in HNF1A MODY Repro 1 cell line). RT-PCR. (C,D). Immunofluorescence staining of pluripotency markers: OCT3/4A, SSEA4, TRA-1-
60, TRA-1-81 in control reprogrammed cells (C) and HNF1A MODY reprogrammed cells (D). Representative pictures (scale bar – 100 mm).
www.nature.com/scientificreports
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mediated differentiation all markers, except FOXA2, were detectable
in control and HNF1A MODY cells (Figure 7B). It must be stressed,
however, that not all RT-PCR analyses produced the positive signals
(Fig. 7C). This might result from a low efficiency of differentiation or
not optimal time-point chosen for particular cell line. Importantly,
markers of pancreatic progenitor cells (HB9, PDX1, NKX2.2, and
NKX6.1) were detectable in each reaction performed (Fig. 7C).
Nevertheless, in all cell lines studied the insulin was expressed at a
very low level, what precluded performing reliable quantitative mea-
surements (Fig. 7A–C). Accordingly, we could not reliably detect C-
peptide in media collected from differentiated cells, however we were
able to measure the concentration of released glucagon (Fig. 7). The
presence of glucagon indicates that utilized protocols enabled gen-
eration of immature, polyhormonal pancreatic cells, which is a usual
outcome of in vitro differentiation methods24.
Discussion
We report in this study the successful generation of murine iPSCs
from wild type and diabetic db/db animals, as well as reprogrammed
human cells from control individuals and diabetic HNF1A MODY
patients. Both mouse iPSCs and human cells expressed pluripotency
markers like Oct3/4A or Nanog and they were able to differentiate in
Figure 5 | Differentiation potential of human control and HNF1A MODY reprogrammed cells. (A,B). Immunofluorescence staining of markers
characteristic for three different germ layers after two weeks of spontaneous differentiation via embryoid bodies. A – differentiating control
reprogrammed cells. B – differentiating HNF1A MODY reprogrammed cells. GATA4 – marker of early and defined endoderm as well as mesoderm;
neurofilament heavy chain (NF-H) – marker of ectoderm; a smooth muscle actin (aSMA) – marker of mesoderm (scale bar – 100 mm). (C). Histological
staining of epithelial tumor formed in immunocompromised mouse after injection of human control reprogrammed cells. Representative pictures (scale
bar – 100 mm).
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 5 : 8597 | DOI: 10.1038/srep08597 7
vitro into cells originating from three different germ layers. After
injections of mouse control and db/db iPSCs into immunocompro-
mised animals we could observe teratoma formation which indicates
that obtained cell lines were pluripotent. Additionally, mouse iPSCs
could be differentiated into endothelial progenitor-like cells positive
for CD34 and Tie-2 markers. Importantly, such iPSc-derived db/db
cells displayed impairment in angiogenic potential similar to that
demonstrated by mature primary endothelial cells isolated from lungs
of db/db mice. In case of human reprogrammed cells, established
control and HNF1A MODY lines did not form teratomas, nonethe-
less, they could be directed to differentiate toward pancreatic lineage.
To the best of our knowledge this is the first report indicating
successful generation of iPSCs from Lepdb/db mice which are the
model of T2D. Liu et al. previously obtained and characterized
iPSCs from NOD mice which are used to study pathophysiology of
diabetes type 119. Additionally, in another study such pluripotent
cells were successfully differentiated into functional pancreatic
beta-like insulin-producing cells which, upon transplantation into
diabetic mice, reversed hyperglycemic phenotype of these animals25.
Endothelial dysfunction is an important complication associated
with T2D26. Both hyperglycemia and insulin resistance contribute to
impaired physiology of endothelial cells by increasing reactive oxy-
Figure 6 | Differentiation of human reprogrammed cells to pancreatic lineage. (A). Schematic representation of direct differentiation method. (B).
Morphological changes of HNF1A MODY Repro 1 line during direct differentiation (scale bar – 100 mm). (C). Schematic representation of embryoid
body-mediated differentiation method. (D). Morphological changes of HNF1A MODY Repro 1 line during embryoid body-mediated differentiation.
Representative pictures (scale bar – 100 mm).
www.nature.com/scientificreports
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Figure 7 | Expression of markers of pancreatic differentiation in cells derived from human control and HNF1A MODY reprogrammed cells. (A).
Expression of markers in cells subjected to direct differentiation method. (B). Expression of markers in cells subjected to embryoid bodies-mediated
method. Agarose gel electrophoresis of representative RT-PCR products. In case of direct differentiation RT-PCR was performed for cells from each
patients and in case of embryoid bodies-mediated differentiation RT-PCR was performed in duplicates. EF2 was used as a housekeeping control for each
performed reaction. (C). The efficiency of detection of pancreatic differentiation markers (both differentiation methods are combined, n 5 3–5).
Percentage of positive RT-PCR results in relation to expression of EF2 housekeeping gene which was detected in all analysed samples. (D). Production of
glucagon in differentiated Panc-1 cells as well as control and HNF-1A MODY reprogrammed cells differentiated with embryoid bodies-mediated method
(EB) and direct method (direct). Medium – media used to perform the last step of differentiation (in case of Panc-1 cells one type of medium was utilized);
cells – media collected from differentiated cells in the last day of differentiation (n 5 2).
www.nature.com/scientificreports
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gen species, production of vasoconstrictive factors, and decreasing
NO bioavailability27. Interestingly, many reports indicated that dia-
betes negatively affects a heterogeneous population of endothelial
(proangiogenic) progenitor cells28,29, claimed to originate from bone
marrow22. Obesity and insulin resistance, the hallmarks of T2D, lead
to elevated leptin levels which in turn can result in tissue leptin
resistance and endothelial dysfunction30. Additionally, leptin recep-
tor was reported to mediate the mobilization of bone marrow-
derived proangiogenic progenitor cells31.
The existence of endothelial progenitors in bone marrow, specific
set of markers which should be used for their characterization, and
their real contribution to the process of angiogenesis is still disput-
able32, hence better models are required. Moreover, leptin whose
signaling pathways exerted through ObR receptor are abrogated in
db/db mice, was previously demonstrated to be a proangiogenic
factor33,34 and regulator of vascular contractility35,36. On the other
hand, hyperleptinemia and tissue leptin resistance, being the hall-
marks of obese diabetic patient and db/db animals, negatively affect
functioning of endothelial cells and constitute important risk factors
for the development of cardiovascular disease30. Taking this into
consideration we decided to evaluate the potential of db/db iPSCs
to differentiate towards endothelial cells. We demonstrated here the
successful generation of CD341Tie-21 population of progenitor-like
cells of endothelial morphology, expressing active endothelial nitric
oxide synthase, from both control and db/db iPSCs. Importantly,
despite similar expression of endothelial markers, the proangiogenic
activities of the db/db iPSC-derived cells were impaired as that of the
mature endothelial cells isolated from db/db mice. This suggests that
iPSC-derived endothelial-like cells may be useful in investigating the
intrinsic cellular mechanisms associated with endothelial dysfunc-
tion in diabetes of different genetic background.
Since expression of CD34 is characteristic for progenitor cells32,
the obtained population of differentiated cells could be considered as
enriched in endothelial progenitor-like cells. The presence of Tie-2
protein, the receptor recognized by angiopoietin-1 (Ang1), a potent
proangiogenic factor37, further confirms their endothelial phenotype.
Interestingly, within the iPSCs colonies from which successful gen-
eration of CD341Tie-21 populations was achieved we observed
lower efficiency of differentiation in db/db cells. This might be in
line with the decreased expression of heme oxygenase-1, angiotensi-
nogen and proteoglycan-4 in db/db iPSCs. Among these factors,
heme oxygenase-1 is required for proper angiogenic function of
mature endothelial cells38 and bone marrow-derived proangiogenic
cells [ref. 22, reviewed in ref. 39]. The role of angiotensinogen and
proteoglycan-4 in endothelial differentiation and physiology has not
been extensively studied, however, they can facilitate development of
hemangioblasts20,21.
Differentiated db/db cells exhibited impaired angiogenic potential
in endothelial sprouting assay. Schiekofer et al. demonstrated that
db/db mice have reduced basal capillary density and impaired ische-
mia-induced vascular remodeling which was associated with altered
expression patterns of angiogenesis-related factors in db/db ani-
mals40. We also showed that proangiogenic cells derived from bone
marrow of db/db mice display lower migratory capacity and reduced
formation of capillaries both in 2D culture on Matrigel and in 3D
culture of spheroids embedded in collagen41. Our present results
could additionally indicate that leptin plays an important role in
embryonic development of endothelial cells, although more studies
are necessary to draw reliable conclusions.
In contrast to human T2D, Maturity Onset Diabetes of the Young
3 is a monogenic disease and results from the mutations in HNF-1a
transcription factor. Although impaired function of only one protein
is linked to the pathophysiology of HNF1A MODY, the molecular
mechanisms responsible for the clinical outcome of the patients are
not fully understood, mainly due to the poor accessibility of affected
tissues. Generation of patient-specific iPSCs could be an important
step to address this issue. Indeed, HNF1A MODY iPSCs have been
already obtained by Teo et al. who utilized Cre-excisible STEMCCA
vector17. However, the authors did not perform pancreatic differenti-
ation of those cells.
The reprogrammed cells obtained in our work expressed pluripo-
tency markers like OCT3/4A, SSEA4, TRA-1-60 and TRA-1-81 and
differentiated in vitro towards cells originating from three germ
layers. However, despite positive staining for pluripotency and lin-
eage-commitment markers, they were not able to form teratomas
after subcutaneous administration into immunocompromised mice.
This could indicate that the obtained cell lines represent only par-
tially reprogrammed cells42. Alternatively, our method of establish-
ing stable iPSC lines could result in heterogeneous population of
partially and fully reprogrammed cells with varying proportions of
both populations. In this scenario, the lack of teratoma formation
could result from too low number of bona fide iPSCs among injected
cells.
Our data indicate that obtained iPSCs could be successfully differ-
entiated into cells of pancreatic lineage, expressing the insulin gene
and producing glucagon. Importantly, in view of this differentiation
potential, lack of teratoma formation can be considered as beneficial
characteristic increasing the safety of possible future clinical utiliza-
tion of such cells. Utilization of such patient-specific cells to generate
cells of pancreatic lineages would provide an excellent tool to study
molecular mechanisms responsible for impaired insulin production
in HNF1A MODY patients and the exact role of HNF-1a in this
process. The proof-of-concept of such approach was provided by
Hua et al. with iPSCs derived from MODY2 patients who carry the
mutations in glucokinase encoding gene18. Those cells could be dif-
ferentiated into mature b cells with similar efficiency as control
counterparts and recapitulated the clinical phenotype of the patients.
This study highlights also the important issue of utilization of proper
control cells which the authors generated by targeted gene modifica-
tions with zinc finger nucleases. Such approach enables the direct
comparison of mutated and corrected cells with the same genetic
background. In our study, the control cells were derived from non-
diabetic individuals so the possibility of differences originating from
different genetic background of HNF1A MODY reprogrammed cells
should be taken into consideration. Nevertheless, the level of express-
ion of insulin gene in our in vitro differentiated pancreatic lineage
was too low for reliable quantitative comparisons and mechanistic
study of molecular pathways. One can suppose that the final steps of
differentiation within in vivo niche can be more effective18
During the revision of this manuscript, Pagliuca et al. reported
novel in vitro differentiation approach leading to generation of func-
tional human pancreatic b cells from pluripotent stem cells24.
Importantly, such stem-cell-derived glucose-responsive and mono-
hormonal insulin-producing b cells demonstrated features of mature
adult counterparts. This is of great importance since previous pro-
tocols, including those utilized in this study enabled predominantly
to obtain immature, polyhormonal cells24,43. Accordingly, our differ-
entiation approaches led to generation of cells expressing insulin and
glucagon.
In summary we report in this study the generation of mouse db/db
iPSCs as well as patient-specific HNF1A MODY reprogrammed cells
which could be considered as important tools for investigation of
molecular mechanisms responsible for pathophysiology of different
types of diabetes. Further studies should elucidate the potential of
such cells in modeling clinical phenotypes observed in diabetic
patients.
Methods
Mice. Lepdb/db and control mice were purchased from Charles River. C57BL/6J mice
(Charles River) were used to prepare mouse embryonic fibroblasts constituting a
feeder layer for the growth of iPSCs. Foxn1nu immunodeficient mice utilized in
teratoma formation assay were purchased from Harlan Laboratories. Mice were
maintained under the specific pathogen free conditions, in individually ventilated
www.nature.com/scientificreports
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cages, with full access to food and water. All procedures involving the use of animals
were performed according to approved guidelines. All animal experiments were
approved by the Local Ethical Committee for Animal Research at the Jagiellonian
University (approval no. 51/2012, 101/2013, 208/2013).
Preparation and culture of murine fibroblasts. Somatic fibroblasts were isolated
from tails of 3–4 month old Lepdb/db (N 5 5) and control mice (N 5 5). Tails were
excised, peeled, minced into smaller pieces and subsequently digested in collagenase
II solution (1.5 mg/mL, Life Technologies) for 3 hours. Tissue fragments were
centrifuged and seeded onto gelatin-coated wells of 6-well plates in DMEM (Lonza)
containing 10% FBS (Lonza), penicillin (100 U/mL) and streptomycin (100 mg/mL,
both from Sigma-Aldrich). The same medium was used for further culture of the cells.
Mouse embryonic fibroblasts (MEFs) were obtained from 13–15 day old C57BL/6J
embryos. After isolation from the uterus, embryos were washed twice in PBS and
subjected to the head and visceral tissues removal. The remaining parts were minced
and digested in 0.25% trypsin/EDTA solution (1 mL per embryo, Lonza) for 2 hours.
Subsequently, fresh DMEM medium containing 10% FBS, penicillin (100 U/mL) and
streptomycin (100 mg/mL) was added (5 mL per embryo), obtained cells and tissue
fragments were centrifuged (200 3 g, 5 minutes) and seeded onto 75 cm2 flasks. The
same type of medium was used for further culture of MEFs. For mitotical inactivation
of these cells, mitomycin C (Sigma-Aldrich) was added to the culture medium at the
concentration of 10 mg/mL for 3 hours. Subsequently, inactivated MEFs (iMEF) were
seeded to constitute a feeder layer for growth of either mouse iPSCs (1.5 3 105 cells/
well of 6-well plate) or human (3 3 105 cells/well of 6-well plate) reprogrammed cells.
Patient selection, skin biopsies and culture of human primary fibroblasts. All
procedures have been performed according to the approved guidelines of Local
Bioethical Committee at the Jagiellonian University, after receiving the informed
consent of all the subjects (Local Bioethical Committee’s approval no. KBET/43/B/
2012). Patients suffering from HNF1A MODY were recruited in the Clinic of
Metabolic Disease, Collegium Medicum of Jagiellonian University, Krakow. HNF1A
MODY Repro 1 cell line was derived from 57 years old female with substitution of
cytosine 811 with thymidine within exon 4 of HNF1A gene leading to replacement of
arginine with tryptophan in protein sequence. HNF1A MODY Repro 2 cell line was
derived from 30 years old male with deletion of thymidine 1137 within exon 6 of
HNF1A gene leading to the shift in protein coding frame. 6 mm skin biopsies were
transferred into PBS (Mg21 and Ca21 free) supplemented with penicillin (100 U/mL),
streptomycin (100 mg/mL) and amphotericin B (10 mg/mL, Sigma-Aldrich). Dermis
was subsequently separated from epidermis and cut into small pieces which were
digested in collagenase II (2.75 mg/mL) and DNaseI (1 mg/mL, Merck) solution.
Released cells and tissue fragments were then centrifuged (200 3 g, 5 minutes),
suspended in fresh DMEM medium containing 10% FBS, penicillin (100 U/mL),
streptomycin (100 mg/mL) and amphotericin B (10 mg/mL) and seeded on a gelatin-
coated wells of 6-well plate. The same medium was used for further culture of human
fibroblasts.
Control, non-diabetic samples were obtained in the Clinic of Surgery, Collegium
Medicum of Jagiellonian University, Krakow, from two non-diabetic patients
undergoing routine surgery. For this purpose, surgical incisions were prolonged for
4–6 mm, and skin biopsies were collected. Further isolation of human fibroblasts was
performed following the same procedures as MODY samples.
Production of VSV-G pseudotyped lentiviral vectors. Production of VSV-G
pseudotyped lentiviral vectors was performed according to the previously described
protocol44. Briefly, 7 3 106 293 T cells (kindly gifted by dr. Maciej Wiznerowicz,
Greater Poland Cancer Center, Poznan, Poland) were seeded onto 10 cm dishes in the
DMEM medium containing 10% FBS, penicillin (100 U/mL) and streptomycin
(100 mg/mL) and subsequently subjected to the triple plasmid transfection with
polyethylenimine (PEI, Polysciences Inc.) as a transfectant reagent. Reprogramming
vectors were produced utilizing hSTEMCCA plasmid construct containing four
transcription factors: OCT3/4A, KLF4, SOX2 and c-MYC within one expression
cassette (kindly provided by dr. Gustavo Mostoslavsky, Boston University, USA45)
whereas in case of control vectors, FUGW plasmid, harboring GFP cDNA, was used
(Addgene 14883). Additionally, psPAX2 and pMD2.G plasmids (kindly provided by
dr Maciej Wiznerowicz, Greater Poland Cancer Center) served as a source of tat, rev,
gag/pol and VSV-G, respectively. 48 h post-transfection, media containing vectors
were collected, filtered through 0.8 mm filters (Millipore), aliquoted, and frozen at
280uC.
Reprogramming of mouse and human fibroblasts. 2.5 3 104 murine fibroblasts
isolated from wild type as well as Lepdb/db mice were seeded on wells of 24-well plate
and transduced with either reprogramming (hSTEMMCA) or control, FUGW
vectors, in the presence of 4 mg/mL of polybrene (Sigma-Aldrich). 24 h post-
transduction media containing vector particles were replaced with fresh culture
media, in which the cells were grown until full confluency. Subsequently, fibroblasts
were trypsinized (0.25% trypsin/EDTA solution) and transferred to the 6-well plates
covered with mitotically inactivated MEFs in the iPSCs medium consisting of DMEM
supplemented with 20% FBS, penicillin (100 U/mL), streptomycin (100 mg/mL), 1%
non-essential amino acids (Life Technologies), 0.1 mM 2-mercaptoethanol (Life
Technologies) and 1000 U/ml leukemia inhibitory factor (LIF, Millipore). The
medium has been changed daily until the colonies resembling embryonic stem cells
emerged. Colonies were subsequently picked, trypsinized (0.25% trypsin/EDTA
solution) and seeded on the new wells of 24-well plate coated with mitotically
inactivated MEFs. Control and Lepdb/db iPSCs were further expanded and
characterized.
For reprogramming of human fibroblasts, 2.5 3 104 control and HNF1A MODY
cells were seeded on gelatin-coated (Sigma-Aldrich) 24-well plates and transduced
with either reprogramming (hSTEMMCA) or control, FUGW vector in the presence
of 4 mg/mL of polybrene (Sigma-Aldrich). 24 h post-transduction media containing
vector particles were replaced with human iPSC medium consisting of KnockOut
DMEM (Life Technologies) supplemented with 20% KnockOut Serum Replacement
(KSR, Life Technologies), penicillin (100 U/mL), streptomycin (100 mg/mL), 1%
non-essential amino acids, 0.1 mM 2-mercaptoethanol and 10 ng/ml of human
bFGF (PeproTech). On 6th day of reprogramming the cells were reseeded on either
mitotically inactivated MEF- or Matrigel- (BD Biosciences) coated 60 mm dishes.
The cells were fed every other day until mature colonies resembling human embry-
onic stem cells emerged.
Picked colonies were mechanically dissociated and seeded onto new Matrigel- or
iMEF-coated 24-well plates. For the improvement of survival the ROCK inhibitor
(10 mM, Abcam) was added to the iPSC culture medium46. The separation of
reprogrammed cells was also carried out by exploiting faster adherence of non-
reprogrammed fibroblasts to gelatin-coated surface. Briefly, cell suspension, disso-
ciated by Accutase (GE Healthcare) was placed on gelatin coated dishes for 35
minutes. Floating cells enriched in human reprogrammed cells were further cultured
on Matrigel-coated dishes. This procedure was repeated 3–4 times to ensure sufficient
removal of non-reprogrammed cells. Reprogrammed lines from two control indivi-
duals (named Ctr Repro 1 and 2) and two HNF1A MODY patients (named HNF1A
MODY Repro 1 and 2) were subsequently expanded and characterized.
Spontaneous differentiation of mouse iPSCs and human reprogrammed cells -
embryoid body formation. To verify the pluripotency of obtained mouse iPSCs and
human reprogrammed cells, in a first step in vitro spontaneous differentiation was
performed. Briefly, mouse iPSCs and human reprogrammed cells growing on iMEF-
coated wells suspended in either mouse iPSC differentiation medium (DMEM
supplemented with 20% FBS, penicillin (100 U/mL), streptomycin (100 mg/mL), 1%
non-essential amino acids and 0.1 mM 2-mercaptoethanol) or human iPSC
differentiation medium (KnockOut DMEM supplemented with 20% KnockOut
Serum Replacement, penicillin (100 U/mL), streptomycin (100 mg/mL), 1% non-
essential amino acids and 0.1 mM 2-mercaptoethanol) and seeded on non-adherent
100 mm dishes. After 5 days, mouse EBs were transferred onto gelatin-coated 48-well
plates and further cultured for 12 days with daily medium change. Similarly, human
EBs were transferred after 5–8 days on Matrigel-coated dishes and cultured for 5–9
days. Both mouse and human differentiated cells were subsequently
immunofluorescently analyzed for expression of markers characteristic for cells
originating from endo-, ecto- and mesoderm.
Teratoma formation assay. Mouse iPSCs were trypsinized and reseeded on gelatin-
coated wells for 1 h to deplete the population of iMEFs. Floating cells were collected,
centrifuged and resuspended in DMEM supplemented with 10% FBS, penicillin
(100 U/mL), and streptomycin (100 mg/mL). 1.5 3 106 cells were injected
subcutaneously into dorsal flank of immunocompromised Fox1nu mice. After
approximately 8 weeks tumors were excised, embedded in paraffin and subjected to
histological analysis with hematoxilin and eosin staining.
Human reprogrammed cells were detached with Accutase, centrifuged and
resuspended in human iPSCs differentiation medium. 1–2 3 106 cells were injected
subcutaneously into dorsal flank of immunocompromised Fox1nu mice. After
approximately 8 weeks the sole resulting tumor were excised, embedded in paraffin
and subjected to histological analysis with hematoxilin and eosin staining.
Differentiation of mouse iPSCs into endothelial cells. Mouse iPSCs were
trypsinized and reseeded on gelatin-coated wells for 1 h to deplete the population of
iMEFs. Floating cells were collected, centrifuged, resuspended in a-MEM (Lonza)
supplemented with 10% FBS, penicillin (100 U/mL), streptomycin (100 mg/mL), 1%
non-essential amino acids and 0.1 mM 2-mercaptoethanol (EDM, endothelial
differentiation medium), and subsequently seeded on 12-well plates coated with
collagen IV (Sigma-Aldrich; 5 mg/cm2, diluted in 50 mM hydrochloric acid). Cells
were cultured for 4 days and then transferred to 12-well plates coated with fibronectin
(Sigma-Aldrich; 20 mg/mL, 15–30 minutes at 37uC) in EDM medium supplemented
with 50 ng/mL VEGF (Sigma-Aldrich). Further passaging was performed whenever
cells reached around 90% confluency. After approximately 30–60 days, when
majority of cells acquired endothelial-like phenotype (CD341Tie-2133), the medium
was changed to EGM-2MV (Lonza) and the cells were further cultured for the
immunophenotyping and functional assays. Differentiated cells could be kept in
culture for at least 130 days without changes in the morphology, phenotype or growth
capacity.
Isolation of lung primary endothelial cells. Lungs from 5 control, wild type and 6
Lepdb/db mice were cut in small pieces and digested in 1 U/mL of dispase for 1 h at
37uC with agitation from time to time. The resulting cell suspension was filtered and
stained with anti-CD34-FITC conjugated antibody (BD Bioscience). Subsequently
cells were incubated with anti-FITC magnetic beads (Myltenyi Biotech) for 15
minutes and separated on AutoMACS (Myltenyi Biotech). CD34 positive cells were
then counted and seeded in EGM-2MV with methylcellulose in U-shaped 96-well
plate for in vitro endothelial sprouting assay. No spheres could be obtained from 2
Lepdb/db mice. In the rest of the sorted cells compact spheres could be formed after 5
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days in culture. The resulting spheres were embedded in collagen I and the sprouting
was assessed after 24 h.
Flow cytometry. In order to immunophenotype the cells during endothelial
differentiation, they were detached with Accutase (Cytogen), washed with PBS and
resuspended in PBS with 2% FBS. Subsequently, the cells were incubated with FcR
blocking reagent (Miltenyi Biotech) for 10 minutes at 4uC followed by addition of
specific antibodies conjugated with fluorochromes: CD34-FITC (BD Biosciences)
and Tie-2-APC (Biolegend). After 30 minutes of incubation at 4uC the cells were
washed with PBS, resuspended in PBS supplemented with 2% FBS and acquired on
LSRII flow cytometer (BD Biosciences). Appropriate single stained samples were used
for compensation of different fluorochromes. Results were analyzed by Diva software
(BD Biosciences).
Endothelial sprouting assay. To form endothelial spheres, differentiating iPSCs at
day 120 of culture were detached with Accutase and transferred to 10 mL of medium
containing methyl cellulose [composed of 10 mL of methyl cellulose (Sigma-Aldrich;
100%) and 40 mL of EGM-2MV medium] to obtain concentration of 7500 cells/mL.
Subsequently, 750 cells/well were seeded on U-shaped 96-well plate in 100 ml of
medium. The plate was incubated at 37uC and the formation of spheres was assessed
after 1–3 days.
After the spheres were formed they were embedded in collagen type I (BD
Biosciences) for evaluation of sprouting capability. Briefly, the spheres were centri-
fuged (45 3 g, 3 minutes, room temperature) and resuspended in 500 mL of methyl
cellulose supplemented with 30% FBS. Subsequently, 500 mL of HBSS containing
phenol red (Sigma-Aldrich) were mixed with 4 mL of 100% collagen I solution
followed with its neutralization with sterile 200 mM NaOH. 500 mL of collagen
solution was mixed with 500 mL of sphere suspension and immediately poured on 24-
well plate. After 15 minutes of incubation at 37uC, the wells were covered with 200 mL
of EGM-2MV medium. The sprouting was assessed after 24 h and 48 h using an
inverted microscope.
Nitric oxide production. The production of NO was measured in the culture
medium of differentiated cells at day 130 of culture, using gas-phase
chemiluminescence reaction. Nitrite, the major oxidation product of NO in the
absence of oxyhemoglobin or superoxide anion, is formed when NO reacts with
dissolved oxygen. Therefore the nitrite formed in the medium was reduced in a
solution of acetic acid in the presence of iodide47 and the measurement was performed
with 280i Nitric Oxide Analyzer (NOATM, Sievers) equipped with high sensitivity
detector for NO.
Pancreatic differentiation - direct method. The direct differentiation approach
follows a modified protocol by Maehr et al.48. Accordingly, human reprogrammed
cells (Ctr Repro 1 and 2 as well as HNF1A MODY Repro 1 and 2) were seeded onto
Matrigel coated 12-well plates. The cells were cultured in human iPSCs medium until
80% confluency was observed followed by the first change to differentiation medium.
During the four differentiation stages the differentiation medium was replaced six
times: at day 1st it composed of Advanced RPMI (Life Technologies) supplemented
with Wnt3a (25 ng/mL, Sigma-Aldrich), Activin A (100 ng/mL, PeproTech), 1%
Glutamax (Life Technologies), penicillin (100 U/mL) and streptomycin (100 mg/
mL); on day 3rd it composed of Advanced RPMI supplemented with 0.2% FBS, Activin
A (100 ng/mL), 1% Glutamax, penicillin (100 U/mL) and streptomycin (100 mg/
mL); on day 5th it composed of Advanced RPMI supplemented with 2% FBS, FGF10
(50 ng/mL, PeproTech), 25 mM KAAD-Cyclopamine (Sigma-Aldrich), 1%
Glutamax, penicillin (100 U/mL) and streptomycin (100 mg/mL), on day 9th it
composed of DMEM supplemented with FGF10 (50 ng/mL), 25 mM KAAD-
Cyclopamine, 2 mM retinoic acid (Sigma-Aldrich), B27 supplement (1x, Life
Technologies), 1% Glutamax, penicillin (100 U/mL) and streptomycin (100 mg/mL);
on day 13th it composed of DMEM supplemented with FGF10 (50 ng/mL), 300 nM
Indolactam V (Sigma-Aldrich), B27 supplement (1x, Life Technologies), 1%
Glutamax, penicillin (100 U/mL) and streptomycin (100 mg/mL); and on day 19th it
composed of DMEM supplemented with 10 mM DAPT (Sigma-Aldrich), B27
supplement (1x), 1% Glutamax, penicillin (100 U/mL) and streptomycin (100 mg/
mL). With every step the morphological changes were documented and RNA was
isolated.
Pancreatic differentiation – embryoid body-based method. The differentiation
approach based on a prior EBs formation was performed according to the modified
protocol described in Schroeder et al.49. Ctr Repro 2 and HNF1A MODY Repro 1
were used in this experiment. EBs were formed as described for spontaneous
Table 1 | Primers used in the study
Gene Species Sequence Product length
Oct3/4A mouse CCCCAATGCCGTGAAGTTGGAGAAGGT 452 bp
TCTCTAGCCCAAGCTGATTGGCGATGTG
Nanog mouse CGTTCCCAGAATTCGATGCTT 102 bp
TTTTCAGAAATCCCTTCCCTCG
Sox2 mouse TGGGAGGAAGAGGTAACCACG 116 bp
ACCTACAGCATGTCCTACTCG
Hmox1 mouse GTGGAGACGCTTTACGTAGTGC 250 bp
CTTTCAGAAGGGTCAGGTGTCC
Agt mouse CCACTGGAGGGGGTCAGTACA 125 bp
GAGATGCTGTTGTCCACCCAGA
Prg4 mouse CGTTGCATCCGAGAACCATG 118 bp
CATCTCCCTGCACAGCTTGA
OCT3/4A human CGGAGCCCTGCACCGTCA 221 bp
GCAGATGGTCGTTTGGCTGAAT
hSTEMCCA_ctr AGGAGCAAAAGCTCATTTCTG 326 bp
TCAGCAAACACAGTGCACACC
SOX17 human AAGGGCGAGTCCCGTATCC 142 bp
TCAGCGCCTTCCACGACTTGC
FOXA2 human ATTGCTGGTCGTTTGTTGTG 187 bp
TACGTGTTCATGCCGTTCAT
HNF4a human CATGGCCAAGATTGACAACCT 113 bp
TTCCCATATGTTCCTGCATCAG
HNF6 human CGCTCCGCTTAGCAGCAT 61 bp
GTGTTGCCTCTATCCTTCCCAT
MNX1 (HB9) human TCCACCGCGGGCATGATCCT 165 bp
GCGCTTGGGCCGCGACAGCTA
PDX1 human CCTTTCCCATGGATGAAGTC 145 bp
CGAACTCCTTCTCCAGCTCTA
NKX6-1 human TCAACAGCTGCGTGATTTTC 126 bp
CCAAGAAGAAGCAGGACTCG
NKX2-1 human ATGTAAACGTTCTGACAACT 228 bp
TTCCATATTTGAGAAATGTTTGC
INS human GCTGGTACAGCATTGTTCCAC 154 bp
CTTCTTCTACACACCCAAGACC
EF2 mouse human GACATCACCAAGGGTGTGCAG 214 bp
TCAGCACACTGGCATAGAGGC
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differentiation of human reprogrammed cells and cultured in non-adherent
conditions for 5 days. Subsequently they were seeded onto Matrigel-coated dishes
(60 mm) for further 9 days in the same medium during which spontaneous
differentiation occurred. On day 14th the cells were washed 2 times with PBS,
trypsinized and removed from the dish surface with a cell scraper. Collected cells were
suspended in differentiation medium composed of DMEM/F12 (Lonza)
supplemented with 10% FBS, 100 mM putrescine (Sigma-Aldrich), 20 nM
progesterone (Sigma-Aldrich), laminin (1 mg/mL, Sigma-Aldrich), insulin (25 mg/
mL, Sigma-Aldrich), 30 nM sodium selenite (Sigma-Aldrich), transferrin (50 mg/mL,
Sigma-Aldrich), B27 supplement (1x), penicillin (100 U/mL) and streptomycin
(100 mg/mL) and seeded onto collagen I coated dishes (1:70 in 0.2 N acetic acid).
Differentiation medium was changed every other day and RNA isolation was
performed on day 19, 24 and 30.
Differentiation of Panc-1 pancreatic cancer cell line. Panc-1 cells (ATCC, CRL-
1469) were cultured in DMEM medium containing 10% FBS, penicillin (100 U/mL)
and streptomycin (100 mg/mL) and differentiated toward insulin- and glucagon-
expressing cells according to Suzuki J et al. protocol50. Briefly, 1 3 106 cells cultured on
6-well plate were washed with PBS and treated for 30 s with 0.05% trypsin/EDTA
solution at room temperature. Trypsin was removed, cells were washed three times
with PBS and subsequently cultured for 6 days in DMEM/F12 medium containing
17.5 mM glucose and 1% BSA. Media were collected and subjected to enzyme
immunoassay (EIA) for measurement of glucagon concentration.
Enzyme immunoassay (EIA). EIA assay (Sigma-Aldrich) for measurement of
glucagon concentration was performed according to manufacturer’s protocol. Media
collected from differentiated Panc-1 cells and from the last day of differentiation of
control and HNF1A MODY reprogrammed cells via direct and EB-mediated
protocols were used.
Isolation of RNA, RT-PCR and real-time qPCR. Total cellular RNA was isolated
utilizing the phenol/chloroform extraction. To ensure complete removal of genomic
DNA contamination samples were treated with DNase I (Life Technologies). Reverse
transcription was performed with M-MuLV Reverse Transcriptase (Thermo
Scientific) and oligo(dT) primers (Promega). PCR reaction was performed using Taq
polymerase (Promega) under following conditions: 95uC for 5 minutes, 40 cycles of
95uC for 30 seconds, annealing temperature for 60 seconds and 72uC for 45 seconds,
with final elongation at 72uC for 5 minutes. The PCR products electrophoresis was
performed in 2% agarose gel. Quantitative real-time PCR with melt curve analysis of
amplified products was performed with StepOne Plus cycler (Applied Biosystems)
and SYBRH Green JumpStartTM Taq ReadyMixTM (Sigma-Aldrich).
In murine iPSCs the expression of Oct3/4A, Nanog, Sox2, Hmox1, Prg4 and Agt was
determined by quantitative RT-PCR, while in human reprogrammed cells OCT3/4A
and markers of pancreatic differentiation were checked48. The applied PCR program
for detection of pancreatic differentiation markers followed the same setting as for
OCT3/4A except for the annealing temperature which was reduced to 54uC and
additionally, 6 mL (instead of 2 mL) of cDNA samples were used. After first exam-
inations the markers with low gene expression, i.e. SOX17 and INS were also amplified
by PCR using a highly sensitive DNA polymerase (Q5HHigh-Fidelity DNA
Polymerase [2000 U/mL], New England Biolabs). In case of direct differentiation RT-
PCR was performed for cells from each patients and in case of embryoid bodies-
mediated differentiation RT-PCR was performed in duplicates. Additionally, silen-
cing of the hSTEMCCA vector was tested by amplification of sequence specific for
transgene cassette with primers designed to recognize c-MYC (forward primer) and
WPRE (reverse primer) part of the vector construct within the cellular transcripts51.
EF2 was used as the housekeeping gene. The sequences of primers used in the study
are provided in Table 1.
Immunofluorescent analysis. Mouse iPSCs and human reprogrammed cells as well
as differentiating cells growing in 48-well plates were washed with PBS, fixed with 4%
paraformaldehyde for 10 minutes in room temperature and permeabilized with 0.1%
Triton-X100 in PBS (10 minutes, room temperature). Cells were washed three times
with PBS, blocked for 1 h in room temperature with 4% BSA in PBS solution and
incubated with the primary antibodies overnight at 4uC. The following primary
antibodies were used: Oct3/4A (1:200, Santa Cruz Biotechnology), Nanog (1:200,
Abcam), SSEA-1 (1:200, Millipore), SSEA-4, TRA-1-60, TRA-1-81 (1:100, Millipore),
Nestin, Vimentin (1:200, Abcam), Neurofilament heavy chain (1:1000, Abcam),
smooth muscle actin (1:100, Abcam), GATA-4 (1:50 for human and 1:200 for murine
cells, Santa Cruz Biotechnology), Nkx2.5 (1:200, Santa Cruz Biotechnology), vWF
(1:100, Abcam), Flt-1 (1:100, Abcam), phospho eNOS (1:100, Abcam).
Subsequently, cells were washed 5 times with PBS and incubated with secondary
antibodies (AlexaFluor, Life Technologies) for 1 h in room temperature. This was
followed by incubation with 1 mg/mL of Hoechst 33342 in PBS for 10 minutes in
room temperature and 4 washing steps with PBS. Cells were eventually visualized
under fluorescent microscope (Nikon Eclipse TS100). Additionally, mouse iPSCs
were stained with CDy1 (kindly provided by dr Young-Tae Chang, Department of
Chemistry, National University of Singapore), a fluorescent dye which selectively
marks mouse and human pluripotent stem cells52. For this purpose, iPSCs were
incubated with 0.1 mg/mL of CDy1 diluted in iPSCs culture medium for 1 h at 37uC.
Cells were than washed with PBS and further cultured for 2 h in fresh medium.
Colonies were visualized under fluorescent microscope.
Statistical analysis. Data are presented as mean 1 SEM. Unpaired two-tailed t-test or
exact Fisher test were used to analyze statistical significance. Results were
considered as significant at p , 0.05.
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